Rates of Infection with Clostridium Difficile Increase Over Time in Patients With Cancer

Share this content:
Over the years included in this analysis, 1.09% of patients with cancer incurred a <i>C difficile</i> infection.
Over the years included in this analysis, 1.09% of patients with cancer incurred a C difficile infection.

Infection with Clostridium difficile in patients with cancer is increasing in frequency and negatively affects clinical and care outcomes, according to the results of a recent study. Patients with cancer experience several risk factors for developing C difficile infection.

Researchers assessed the incidence of C difficile infection in patients with cancer via the National Hospital Discharge Database from 2001 to 2010. This study used diagnosis codes to determine which patients with cancer also experienced C difficile infection.

Over the years included in the analysis, 20.1 million discharged patients had a cancer diagnosis. C difficile infection developed in 1.09% of patients with cancer and 0.77% of patients without cancer (adjusted odds ratio [aOR], 1.28; 95% CI, 1.28-1.29; P <.001).

During the 10 years examined in this study, the frequency of infection with C difficile in patients with cancer increased from 64.7 per 10,000 discharges between 2001 and 2002 to 109.1 per 10,000 between 2009 and 2010 (P <.001).

Patients with cancer and C difficile infection experienced longer than average lengths of stay (5.67 days; 95% CI, 5.39-5.94), higher rates of in-hospital mortality (aOR, 1.18; 95% CI, 1.16-1.20), and higher rates of discharge to a care facility (aOR, 1.74; 95% CI, 1.72-1.75; all P <.001) compared with patients with cancer without C difficile infection.


1. Gupta A, Tariq R, Frank RD, et al. Trends in the incidence and outcomes of hospitalized cancer patients with Clostridium difficile infection: a nationwide analysis. J Natl Compr Canc Netw. 2017;15:466-472.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs